Australia markets closed

ZIVO Bioscience, Inc. (9R8.SG)

Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
3.21000.0000 (0.00%)
At close: 07:12PM CET
Full screen
Previous close3.2100
Open0.5850
Bid0.5350 x N/A
Ask0.5450 x N/A
Day's range0.5350 - 3.2100
52-week range0.5350 - 19.3200
Volume0
Avg. volume0
Market cap5.591M
Beta (5Y monthly)0.24
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    ZIVO Bioscience Reports Additional Findings from Positive 42-Day Coccidiosis Challenge Study

    BLOOMFIELD HILLS, Mich., February 07, 2024--Zivo Bioscience, Inc. (OTCQB: ZIVO) (the "Company"), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces additional findings from its 42-day coccidiosis challenge study that demonstrate the product’s positive impact on the cost of broiler production as an alternative to commonly-used antibiotics.

  • Business Wire

    ZIVO Bioscience Announces Uplisting to OTCQB Market

    BLOOMFIELD HILLS, Mich., January 29, 2024--Zivo Bioscience, Inc. (OTCQB: ZIVO) (the "Company"), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces it has uplisted the trading of shares of its common stock from the OTC® Pink Market to the OTCQB® Venture Market (OTCQB), effective as of the opening of trading on Friday, January 26, 2024. Following this uplisting, ZIVO Bioscience cont

  • Business Wire

    ZIVO Bioscience Reports Positive Efficacy Results from 42-Day Validation Study with Non-Antibiotic Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens

    BLOOMFIELD HILLS, Mich., January 23, 2024--Zivo Bioscience, Inc. (OTC PINK: ZIVO) (the "Company"), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces positive efficacy results following its recent 42-day coccidiosis challenge study further demonstrating the effectiveness of its novel immune-modulating treatment for coccidiosis in broiler chickens. ZIVO’s product candidate for use